Remove Contract Manufacturing Remove Manufacturing Remove Trials
article thumbnail

India’s contract manufacturing gains momentum due to high quality & cost effectiveness: Expert

AuroBlog - Aurous Healthcare Clinical Trials blog

India is strengthening its scope in contract manufacturing as the global customers commend the strengths and dependability of its pharma and biotech sectors.

article thumbnail

Clinical trial packaging services in contract manufacturing for the pharmaceutical industry

Pharmaceutical Technology

Pharmaceutical Technology Has Listed Some of the Leading Providers of Clinical Trial Packaging Services. Download For Free Here.

Packaging 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

About the Pharma Contract Manufacturing

Creogenic Pharma

Pharma Contract Manufacturing: From the pharmaceutical sector there is a group of businesses that have tasked themselves to assist other businesses to provide better solutions to customers. The CMO supplies technical services assisting the consumer to prevent liability for the hidden costs that may include manufacturing.

article thumbnail

Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trial

BioPharma Reporter

Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.

article thumbnail

Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir

pharmaphorum

Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.

article thumbnail

Analyzing the impact of biosimilars on biologic drug manufacturing technologies

Drug Patent Watch

As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies. This article delves into the impact of biosimilars on biologic drug manufacturing technologies, highlighting the challenges, opportunities, and future directions in this field.

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).

RNA 245